The current study identifies a new bispecific modality that simultaneously inhibits PD‐1/PD‐L1 and RANK/RANKL in the TME, providing benefit in ICI‐resistant settings and demonstrating superior anti‐tumor control compared with the combination of parental anti‐RANKL plus anti‐PD‐1 antibodies. This evidence concerns the gene TNFRSF11A and neoplasm.